Antigen-specific therapies in multiple sclerosis. (Q36327373)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16318988%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

review article

1 reference

title

Antigen-specific therapies in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16318988%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16318988%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Roland Martin

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16318988%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1

Mireia Sospedra

1 reference

13 August 2017

Roland Martin

2

1 reference

13 August 2017

publication date

1 September 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16318988%20AND%20SRC:MED&resulttype=core&format=json

International Reviews of Immunology

9 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16318988%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16318988%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

5-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16318988%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

393-413

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16318988%20AND%20SRC:MED&resulttype=core&format=json

Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Antigen-driven bystander suppression after oral administration of antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-beta mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Effective antigen-specific immunotherapy in the marmoset model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Myelin-specific tolerance attenuates the progression of a virus-induced demyelinating disease: implications for the treatment of MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Autoantigen-pulsed dendritic cells induce tolerance to experimental allergic encephalomyelitis (EAE) in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Antigen-specific inhibition of the adoptive transfer of experimental autoimmune encephalomyelitis in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Antigen-Specific Tolerance as a Therapy for Experimental Autoimmune Encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Cell-based gene therapy experiments in murine experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Gene therapy in a murine model for clinical application to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

A novel retroviral gene therapy approach to inhibit specific antibody production and suppress experimental autoimmune encephalomyelitis induced by MOG and MBP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Peptidic complex mixtures as therapeutic agents in CNS autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T cell interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Regulatory circuits in autoimmunity: recruitment of counter-regulatory CD8+ T cells by encephalitogenic CD4+ T line cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

MHC-Restricted Depletion of Human Myelin Basic Protein-Reactive T Cells by T Cell Vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

T cell vaccination in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Targeting autoantigen-specific T cells and suppression of autoimmune encephalomyelitis with receptor-modified T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

Vaccination against autoimmune encephalomyelitis with T-lymphocite line cells reactive against myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08830180500371256

10.1080/08830180500371256

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16318988%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference